Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
155 Leser
Artikel bewerten:
(2)

ReCept Pharmacy to Distribute Otezla (apremilast): The First FDA Approved Oral Medication for the Treatment of Psoriatic Arthritis for Adults

FORT WORTH, Texas, April 14, 2014 /PRNewswire/ --ReCept announces that it is among a select group of specialty pharmacies selected by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule which works by blocking the enzyme phosphodiesterase 4 to reduce swelling in joints and improve physical function in a form of arthritis that afflicts psoriasis sufferers. Approved by the FDA on March 21, 2014 and available for dispensing on April 9, ReCept has immediate access to dispense Otezla® at initial launch.

According to the National Psoriasis Foundation, approximately 10 to 30 percent of people with psoriasis will develop psoriatic arthritis. Psoriasis is the most prevalent chronic inflammatory disease in the U.S.

Otezla® is the first oral therapy approved to treat active psoriatic arthritis. In clinical trials, Otezla® demonstrated the ability to reduce the signs and symptoms of psoriatic arthritis. Patients treated with Otezla® showed improvement in signs and symptoms of PsA, including tender and swollen joints and physical function, compared to placebo.

As a specialty pharmacy, ReCept is committed to providing patients with optimal outcomes for psoriatic arthritis. Through the use of robust medications like Otezla® in combination with ReCept's 'making people feel better' clinical approach to patient management, patients are able to take full advantage of treatment and maximize clinical benefit.

About ReCept Pharmacy

As a leader in the Specialty Pharmacy industry in the Southwest, ReCept cares for patients throughout a regional network of pharmacies located in Texas. With over 35 years of experience in providing pharmacy care, ReCept employs a knowledgeable, dedicated clinical staff to manage patients with complex chronic conditions. ReCept specializes in serving patients and their treating physicians within the therapeutic classes of Autoimmune, Hepatitis, HIV, Oncology, Compounding and Pain Management. Taking a holistic approach to patient management, ReCept understands specific disease states, their treatments and the effects those treatments have on individual patients. An avid commitment to keep patients adherent and compliant with their treatment regimen is ongoing. The ReCept corporate mission is simple: "To make people feel better" and improve their overall quality of life. For additional information on ReCept Pharmacy, please visit: www.receptrx.com

SOURCE ReCept Pharmacy

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.